Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2082035 | 1.00 | DRD4 (0.39) | DRD4UTS2ROPRM1OPRD1OPRK1 | |
| SCHEMBL2266250 | 0.90 | KDM4D (0.42) | OPRM1OPRD1OPRK1OPRL1CYP2D6 | |
| SCHEMBL4748025 | 0.85 | KMT2A (0.36) | UTS2ROPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL31401115 | 0.83 | KMT2A (0.39) | UTS2RCYP2D6CTSL | |
| SCHEMBL6008976 | 0.83 | KMT2A (0.39) | UTS2RCYP2D6CTSL | |
| SCHEMBL2082300 | 0.81 | KMT2A (0.51) | UTS2RATMHSD11B1 | |
| SCHEMBL2082301 | 0.81 | KMT2A (0.51) | UTS2RATMHSD11B1 | |
| SCHEMBL4712485 | 0.81 | LMNA (0.45) | DRD4UTS2RCHRM4CCR5LMNA | |
| SCHEMBL6204723 | 0.80 | UTS2R (0.36) | UTS2ROPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL6204726 | 0.80 | UTS2R (0.36) | UTS2ROPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902226-B2 | Dehalogeno-compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| EP-1336611-B1 | DEHALOGENO COMPOUNDS | DAIICHI SEIYAKU CO (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20070123560-A1 | Dehalogeno-compounds | DAIICHI PHARMACEUTICAL CO., LTD. | 2007-05-31 | — | — | US | disclosed |
| US-20040063754-A1 | Dehalogeno compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1336611-A1 | DEHALOGENO COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063754-A1 | Dehalogeno compounds | DEK, PGLS, RPS27L | DRD4 250/4885UTS2R 2122/4885OPRM1 704/4885 |
| US-20070123560-A1 | Dehalogeno-compounds | DEK, RPS27L, POLL | DRD4 428/4885UTS2R 2662/4885OPRM1 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.